Insider Selling: Bioventus Inc. (NYSE:BVS) CFO Sells 6,498 Shares of Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 6,498 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $66,214.62. Following the completion of the transaction, the chief financial officer now owns 118,817 shares of the company’s stock, valued at $1,210,745.23. The trade was a 5.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Mark Leonard Singleton also recently made the following trade(s):

• On Monday, December 23rd, Mark Leonard Singleton sold 10,733 shares of Bioventus stock. The shares were sold at an average price of $10.53, for a total value of $113,018.49.

Bioventus Trading Up 0.6 %

Shares of Bioventus stock opened at $10.01 on Friday. The firm has a market cap of $812.31 million, a price-to-earnings ratio of -16.41 and a beta of 0.85. The business has a 50-day moving average price of $10.32 and a 200-day moving average price of $10.86. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a twelve month low of $3.90 and a twelve month high of $14.38.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Canaccord Genuity Group upped their target price on Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and increased their target price for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. CWM LLC purchased a new position in Bioventus in the third quarter worth about $89,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Bioventus during the third quarter valued at approximately $286,000. Olympiad Research LP bought a new position in Bioventus in the third quarter worth approximately $251,000. Principal Financial Group Inc. bought a new position in Bioventus in the third quarter worth approximately $210,000. Finally, Covestor Ltd purchased a new position in Bioventus in the third quarter worth $69,000. Hedge funds and other institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.